What does Oruka Therapeutics, Inc. do?
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for…
What is Oruka Therapeutics, Inc.'s P/E and P/B ratio?
Oruka Therapeutics, Inc. has a P/E ratio of -39.8 and a P/B ratio of 4.83.
What is Oruka Therapeutics, Inc.'s debt-to-equity ratio?
Oruka Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Oruka Therapeutics, Inc. owe compared with what it owns?
Oruka Therapeutics, Inc. owes $0.02 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Oruka Therapeutics, Inc.'s Positivity rank?
Oruka Therapeutics, Inc. is ranked #5,216 of 6,774 companies globally and #2,797 of 4,000 in United States on PositoAI, with a Positivity Score of 18,079.
Does Oruka Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Oruka Therapeutics, Inc..
Where can I read the latest news about Oruka Therapeutics, Inc.?
Recent headlines about Oruka Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Oruka Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Oruka Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.